初级激素受体阳性乳腺癌中的免疫疗法:系统性审查
Maria-Theodora Melissari1, Alkistis Papatheodoridi1, Athanasios Argyriadis2
1Department of Clinical Therapeutics, Medical School of National and Kapodistrian University of Athens, "Alexandra" General Hospital of Athens, Athens, Greece.
Critical reviews in oncology/hematology
|May 22, 2025
概括
用免疫检查点抑制剂 (ICI) 进行的免疫疗法对激素受体阳性,HER2阴性乳腺癌 (BC) 显示出有前途. 然而,临床益处仅限于基于瘤分子形状的特定患者亚组.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 乳腺癌研究研究 乳腺癌研究
背景情况:
- 激素受体阳性 (HR+),HER2阴性乳腺癌 (BC) 通常被认为是免疫学上沉默的.
- 这一特征在历史上已经减缓了对这种特定的乳腺癌亚型免疫疗法的研究.
研究的目的:
- 系统地审查评估免疫检查点抑制剂 (ICI) 在原发性HR+/HER2-非转移性乳腺癌中的安全性和有效性的临床试验.
- 为了概述目前ICI研究在这个患者群体中的现状.
主要方法:
- 在2022年10月30日之前进行文献搜索,以确定相关的临床试验.
- 包括专注于非转移性HR+/HER2-乳腺癌免疫检查点抑制剂的试验.
主要成果:
- 确定了39项试验,主要是在早期阶段;没有发现ICI单疗试验.
- 目前只有2个第三期试验正在进行中,大多数试验都在探索ICI与化学疗法结合在新辅助剂环境中.
- 在报告结果的18项试验中,有6项为HR+/HER2-BC提供了特定的疗效数据.
结论:
- 免疫检查点抑制剂 (ICI) 是对HR+/HER2-乳腺癌的潜在有前途的治疗策略.
- ICI的临床益处似乎仅限于特定的患者亚组,取决于瘤的分子形状.
相关概念视频
Tumor Immunotherapy
677
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
677
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Vaccines
523
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
523
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


